VEGFA and Abnormal retinal morphology: VEGF-A antibodies, delivered intravitreally, represent an FDA-approved therapy in retinal diseases such as AMD and DR [38], [39] and include Lucentis (ranibizumab, Genentech) and Avastin (bevacizumab, Genentech).